Resource Logo

AZT Therapy in infected people: efficacy and side effects.


Int Conf AIDS. 1989 Jun 4-9;5:408 (abstract no. W.B.P.338). Unique

OBJECTIVE: To study the efficacy and toxicity of long term administration of Zidovudine (AZT). METHODS: From August 1987 to December 1988, 48 HIV Ab+ve subjects with various clinical features (5 0I-AIDS, 2 SK-AIDS, 27 ARC-CDC IVa, 14 SF/PGL (WR5) were treated with AZT (18 mg/kg/d) for an average period of 9 months. RESULTS and CONCLUSION: Nine/48 patients (5 AIDS + 2 ARC) developed Opportunistic Infections during the treatment period. An important improvement of lymphocytes number was found in 26/48 patients, but the CD4+ cells have raised significantly in 18 patients. Clinical side effects occurred in 19 patients as follow: slight fever (11), nausea (7), headache (4), rash (4) and convulsions (2). The most important adverse reactions were haematologic - TABLE I. TABULAR DATA, SEE ABSTRACT VOLUME. After 4 months 5/25 patients needed blood transfusions for severe anemia and therapy became less and then was stopped. A raise of MCV was seen in 20/25 subjects. Analysis of red cells volume histogram showed a progressive appearance of a double peak picture due to the arise of a new population of red cells with higher size, although the average MCV could be within normal values. We underline the opportunity of including this analysis to monitor the hematologic side effects of AZT therapy.

Acquired Immunodeficiency Syndrome/*DRUG THERAPY AIDS-Related Complex/*DRUG THERAPY CD4-Positive T-Lymphocytes Human Leukocyte Count Zidovudine/ADVERSE EFFECTS/*THERAPEUTIC USE ABSTRACT


Information in this article was accurate in September 30, 1990. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.